3D bioprinted epicardial patch of GelMA containing VEGF-loaded chitosan nanoparticles and human bone marrow mesenchymal stem cells for the treatment of myocardial infarction
Source abstract
Abstract
Abstract The transplantation of human bone marrow mesenchymal stem cells (hMSCs) exhibits promising therapeutic effects in the treatment of myocardial infarction (MI), however, its clinical application is limited due to the low survival rate of the transplanted cells. Three-dimensional (3D) bioprinted tissue engineering patches have demonstrated efficacy as a delivery approach to enhance the viability and engraftment of stem cells. In this study, we have developed a novel hMSCs tissue-engineered patch equipped with a nano-slow-release system using 3D bioprinting technology. The patch is based on a matrix material consisting of methacrylated gelatin (GelMA) and chitosan nanoparticles loaded with vascular endothelial growth factor (VEGF), which possesses pro-angiogenic effects. The resulting patch demonstrated excellent compatibility with hMSCs and enabled stable, sustained VEGF release. In vivo results showed that the patch significantly reduced cardiomyocyte apoptosis three days after MI, and improved cardiac function and myocardial fibrosis at 28 d post-surgery. These effects were closely associated with the patch’s potent angiogenic properties and favorable stem cell survival. In conclusion, this study successfully developed a 3D-printed tissue engineering patch with strong potential for clinical application, offering a promising new approach for the treatment of MI.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Mesenchymal stem cell research · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Global epidemiology of ischemic heart disease: results from the global burden of disease study10.7759/cureus.9349 ↗
2. Establishment and validation of a prediction nomogram for heart failure risk in patients with acute myocardial infarction during hospitalization10.1186/s12872-023-03665-2 ↗
3. In-hospital predictors for primary prevention of sudden death after acute myocardial infarction with cardiac dysfunction10.1016/j.jjcc.2023.05.003 ↗
4. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial10.1016/j.jacc.2014.12.038 ↗
5. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial10.1016/j.jacc.2014.03.014 ↗
6. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention10.1093/eurheartj/eht369 ↗
7. Stem cell-based therapy in cardiac repair after myocardial infarction: promise, challenges, and future directions10.1016/j.yjmcc.2023.12.009 ↗
8. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy10.1161/CIRCINTERVENTIONS.114.001436 ↗
9. Stem cell therapy for acute myocardial infarction: mesenchymal stem cells and induced pluripotent stem cells10.1080/14712598.2023.2245329 ↗
10. Bone-derived Nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction10.1186/s13287-019-1217-x ↗
11. Lower senescence of adipose-derived stem cells than donor-matched bone marrow stem cells for surgical ventricular restoration10.1089/scd.2017.0271 ↗
12. Ultrasound-targeted microbubble destruction promotes PDGF-primed bone mesenchymal stem cell transplantation for myocardial protection in acute myocardial infarction in rats10.1186/s12951-023-02204-7 ↗
13. Comparative analyses of immunosuppressive characteristics of bone-marrow, Wharton’s jelly, and adipose tissue-derived human mesenchymal stem cells10.4274/tjh.2016.0171 ↗
14. Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation10.1007/s00395-011-0168-x ↗
15. Tracking cardiac engraftment and distribution of implanted bone marrow cells: comparing intra-aortic, intravenous, and intramyocardial delivery10.1016/j.jtcvs.2008.11.001 ↗
16. Combined treatment of human induced pluripotent stem cell-derived cardiomyocytes and endothelial cells regenerate the infarcted heart in mice and non-human primates10.1161/CIRCULATIONAHA.122.061736 ↗
17. Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells10.1016/j.biomaterials.2011.11.003 ↗
18. Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction10.1016/j.biomaterials.2015.05.005 ↗
19. A bioprinted cardiac patch composed of cardiac-specific extracellular matrix and progenitor cells for heart repair10.1002/adhm.201800672 ↗
20. 3D-bioprinted GelMA scaffold with ASCs and HUVECs for engineering vascularized adipose tissue10.1021/acsabm.3c00964 ↗
21. 3D bioprinting of methylcellulose/gelatin-methacryloyl (MC/GelMA) bioink with high shape integrity10.1021/acsabm.0c00169 ↗
22. Biodegradable polymeric nanoparticles based drug delivery systems10.1016/j.colsurfb.2009.09.001 ↗
23. Chitosan-based delivery systems for protein therapeutics and antigens10.1016/j.addr.2009.11.009 ↗
24. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
25. Design and fabrication of GelMA/chitosan nanoparticles composite hydrogel for angiogenic growth factor delivery10.1080/21691401.2017.1392970 ↗
26. Chitosan nanoparticle loaded by epidermal growth factor as a potential protein carrier for wound healing: in vitro and in vivo studies10.1049/nbt2.12116 ↗
27. VEGFA and tumour angiogenesis10.1111/joim.12019 ↗
28. Expression of vascular endothelial growth factor in cardiac repair: signaling mechanisms mediating vascular protective effects10.1016/j.ijbiomac.2018.02.111 ↗
29. Study on the expression of VEGF and HIF-1α in infarct area of rats with AMI
30. Correlation of plasma vascular endothelial growth factor and endostatin levels with symptomatic intra- and extracranial atherosclerotic stenosis in a Chinese Han population10.1016/j.jstrokecerebrovasdis.2016.12.021 ↗
31. Chinese medicine GeGen-DanShen extract protects from myocardial ischemic injury through promoting angiogenesis via up-regulation of VEGF/VEGFR2 signaling pathway10.1016/j.jep.2020.113475 ↗
32. Chinese medicine She-Xiang-Xin-Tong-Ning, containing moschus, corydalis and ginseng, protects from myocardial ischemia injury via angiogenesis10.1142/S0192415X20500068 ↗
33. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique10.1016/j.colsurfb.2011.09.042 ↗
34. Stem cell engraftment and survival in the ischemic heart10.1016/j.athoracsur.2011.07.012 ↗
35. Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application10.1111/j.1582-4934.2010.01078.x ↗
36. Cardiac extracellular matrix-fibrin hybrid scaffolds with tunable properties for cardiovascular tissue engineering10.1016/j.actbio.2014.11.035 ↗
37. Aged human cells rejuvenated by cytokine enhancement of biomaterials for surgical ventricular restoration10.1016/j.jacc.2012.08.985 ↗
38. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells10.4049/jimmunol.179.5.2824 ↗
39. Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis10.1016/j.vph.2014.06.004 ↗
40. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives10.3727/096368913X667709 ↗
41. Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats10.1097/00019501-200506000-00006 ↗
42. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions10.1016/j.febslet.2007.07.028 ↗